Nevertheless, GLP-1 presented a rather ephemeral circulatory half-life, lasting a mere 12 min, due to the rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-4), which markedly limits its biological efficacy [3,4,5]
However, amylin-based therapies are clearly still of interest because AZ has recently presented early data for its long-acting amylin receptor agonist, for AZD6234
The $150 monthly difference between compounded semaglutide and tirzepatide ($199 vs $349) matters for long-term affordability
The success of GLP-1 drugs has expanded investor interest in names like Eli Lilly, which was up almost 8% in the past five days (as of June 9, 2026) due to its new retatrutide drug
The product has different labels depending on the regulatory classification in each country
Eat smaller, lower-fat meals when you start therapy and avoid large volumes that trigger nausea